GlassScriptPhysician profile
Lydia Gilbert-Mcclain
NPI 1861513301
$67,710.27
in general payments reported to CMS, 2019-2025
8 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $14K · 2022: $13K · 2023: $4,225 · 2024: $813 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,343.50 |
| Food and Beverage | $125.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16,687.34 | 2019-2020 | |
| Chiesi USA, INC. | $16,560.50 | 2022-2025 | |
| Aquestive Therapeutics, INC. | $12,908.00 | 2025 | |
| Orphai Therapeutics INC. | $10,129.17 | 2022-2025 | |
| Vectura Limited | $6,000.00 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $5,200.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.27 | 2025 | Ofev |
| Genentech USA, INC. | $99.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Gilbert-Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.